Exact Mass: 436.2788862
Exact Mass Matches: 436.2788862
Found 500 metabolites which its exact mass value is equals to given mass value 436.2788862,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
DHAP(18:0)
C21H41O7P (436.25897660000004)
DHAP(18:0) is the octadecanoyl derivative of Dihydroxyacetone phosphate. It is also known as an alkyl-DHAP. This compound is formed by octadecanoic acid reacting with DHAP. Alkyl-DHAPs are intermediates in the synthesis of ether phospholipids. The initial steps of ether phospholipid biosynthesis take place in peroxisomes. Alkyl-dihydroxyacetonephosphate synthase is the peroxisomal enzyme that actually introduces the ether linkage. Levels of Alkyl-DHAP have been found to be strongly reduced in human fibroblasts derived from Zellweger syndrome and rhizomelic chondrodysplasia punctata patients. Four other enzymes are known to be involved in the metabolism of acyl-DHAP and alkyl-DHAP. These include: acyl-DHAP/alkyl-DHAP oxidoreductase, DHAP acyltransferase, alkyl-DHAP phosphohydrolase, and a dinitrofluorobenzene-insensitive acyl-DHAP acylhydrolase. Dihydroxyacetone phosphate (DHAP) is a biochemical compound primarily involved in the glycolysis metabolic pathway. DHAP is also the product of the dehydrogenation of L-glycerol-3-phosphate which is part of the entry of glycerol (sourced from triglycerides) into the glycolytic pathway. Conversely, reduction of glycolysis-derived DHAP to L-glycerol-3-phosphate provides adipose cells with the activated glycerol backbone they require to synthesize new triglycerides. Both reactions are catalyzed by the enzyme glycerol 3-phosphate dehydrogenase with NAD+/NADH as cofactor. DHAP may be referred to as glycerone phosphate in older texts. 1-Octadecyl-glycerone-3-phosphate is an intermediate in Ether lipid metabolism. DHAP(18:0) or 1-Octadecanoyl-glycerone-3-phosphate is the precursor to 1-Octadecyl-glycerone-3-phosphate DHAP(18:0e) which is generated via alkylglycerone phosphate synthase (EC: 2.5.1.26). Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. Ether lipids are called plasmalogens (1-O-1-alkenyl-2-acylglycerophospholipids) if these are glycerol-containing phospholipids with an unsaturated O-(1-alkenyl) (vinyl ether) group at the first position on the glycerol chain. Plasmalogens as well as some 1-O-alkyl lipids are ubiquitous and sometimes major parts of the cell membranes in mammals and anaerobic bacteria. In archaea, ether lipids are the major polar lipids in the cell envelope and their abundance is one of the major characteristics that separate this group of prokaryotes from the bacteria. In these cells, diphytanylglycerolipids or bipolar macrocyclic tetraethers can form covalently linked bilayers. [HMDB] DHAP(18:0) is the octadecanoyl derivative of dihydroxyacetone phosphate. It is also known as an alkyl-DHAP. This compound is formed by octadecanoic acid reacting with DHAP. Alkyl-DHAPs are intermediates in the synthesis of ether phospholipids. The initial steps of ether phospholipid biosynthesis take place in peroxisomes. Alkyl-dihydroxyacetonephosphate synthase is the peroxisomal enzyme that actually introduces the ether linkage. Levels of Alkyl-DHAP have been found to be strongly reduced in human fibroblasts derived from Zellweger syndrome and rhizomelic chondrodysplasia punctata patients. Four other enzymes are known to be involved in the metabolism of acyl-DHAP and alkyl-DHAP. These include: acyl-DHAP/alkyl-DHAP oxidoreductase, DHAP acyltransferase, alkyl-DHAP phosphohydrolase, and a dinitrofluorobenzene-insensitive acyl-DHAP acylhydrolase. Dihydroxyacetone phosphate (DHAP) is a biochemical compound primarily involved in the glycolysis metabolic pathway. DHAP is also the product of the dehydrogenation of L-glycerol-3-phosphate which is part of the entry of glycerol (sourced from triglycerides) into the glycolytic pathway. Conversely, reduction of glycolysis-derived DHAP to L-glycerol-3-phosphate provides adipose cells with the activated glycerol backbone they require to synthesize new triglycerides. Both reactions are catalyzed by the enzyme glycerol 3-phosphate dehydrogenase with NAD+/NADH as cofactor. DHAP may be referred to as glycerone phosphate in older texts. 1-Octadecyl-glycerone-3-phosphate is an intermediate in Ether lipid metabolism. DHAP(18:0) or 1-Octadecanoyl-glycerone-3-phosphate is the precursor to 1-Octadecyl-glycerone-3-phosphate DHAP(18:0e) which is generated via alkylglycerone phosphate synthase (EC: 2.5.1.26). Ether lipids are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. Ether lipids are called plasmalogens (1-O-1-alkenyl-2-acylglycerophospholipids) if these are glycerol-containing phospholipids with an unsaturated O-(1-alkenyl) (vinyl ether) group at the first position on the glycerol chain. Plasmalogens as well as some 1-O-alkyl lipids are ubiquitous and sometimes major parts of the cell membranes in mammals and anaerobic bacteria. In archaea, ether lipids are the major polar lipids in the cell envelope and their abundance is one of the major characteristics that separate this group of prokaryotes from the bacteria. In these cells, diphytanylglycerolipids or bipolar macrocyclic tetraethers can form covalently linked bilayers. (Wikipedia)
simvastatin hydroxy acid
simvastatin hydroxy acid is a metabolite of simvastatin. Simvastatin is a hypolipidemic drug used to control elevated cholesterol, or hypercholesterolemia. It is a member of the statin class of pharmaceuticals. Simvastatin is a synthetic derivate of a fermentation product of Aspergillus terreus. The drug is marketed generically and under the trade name Zocor. (Wikipedia) C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor
LysoPA(18:1(9Z)/0:0)
C21H41O7P (436.25897660000004)
LysoPA(18:1(9Z)/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
Pangamic acid
Pangamic acid is found in apricot. Pangamic acid is isolated from apricot kernel, also said to be present in cereals etc. Said to be a vitamin of significance in, inter alia, hypertension control Pangamic acid is also known as vitamin B15, but it is not widely accepted as a vitamin for it has not been shown to be essential in the human diet, and a deficiency in consumption of pangamic acid is not known to be associated with any disease. Pangamic acid is an ester derived from gluconic acid and dimethylglycine. It was first isolated by Ernst T. Krebs from apricot kernels, and has since been identified in some foods such as pulses. Also found in rice bran & apricot kernels Isolated from apricot kernel, also said to be present in cereals etc. Said to be a vitamin of significance in, inter alia, hypertension control
LysoPA(0:0/18:1(9Z))
C21H41O7P (436.25897660000004)
LysoPA(0:0/18:1(9Z)) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
(R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol
(R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol is found in fruits. (R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol is a constituent of calabash tree (Crescentia cujete) fruits. Constituent of calabash tree (Crescentia cujete) fruits. (R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol is found in fruits.
(2-Hydroxy-3-phosphonooxypropyl) octadec-9-enoate
C21H41O7P (436.25897660000004)
N,N-Dihexyl-2-(4-fluorophenyl)indole-3-acetamide
C28H37FN2O (436.28897639999997)
DG(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)/0:0)
DG(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0/0:0)
DG(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:3(5Z,8Z,11Z)-O(14R,15S))
DG(2:0/0:0/20:3(5Z,8Z,11Z)-O(14R,15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,8Z,11Z)-O(14R,15S)/0:0/2:0)
DG(20:3(5Z,8Z,11Z)-O(14R,15S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)/0:0)
DG(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0/0:0)
DG(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:3(5Z,8Z,14Z)-O(11S,12R))
DG(2:0/0:0/20:3(5Z,8Z,14Z)-O(11S,12R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,8Z,14Z)-O(11S,12R)/0:0/2:0)
DG(20:3(5Z,8Z,14Z)-O(11S,12R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0)
DG(2:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:3(5Z,11Z,14Z)-O(8,9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,11Z,14Z)-O(8,9)/2:0/0:0)
DG(20:3(5Z,11Z,14Z)-O(8,9)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(5Z,11Z,14Z)-O(8,9)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:3(5Z,11Z,14Z)-O(8,9))
DG(2:0/0:0/20:3(5Z,11Z,14Z)-O(8,9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(5Z,11Z,14Z)-O(8,9)/0:0/2:0)
DG(20:3(5Z,11Z,14Z)-O(8,9)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0)
DG(2:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:3(8Z,11Z,14Z)-O(5,6)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(8Z,11Z,14Z)-O(5,6)/2:0/0:0)
DG(20:3(8Z,11Z,14Z)-O(5,6)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(8Z,11Z,14Z)-O(5,6)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:3(8Z,11Z,14Z)-O(5,6))
DG(2:0/0:0/20:3(8Z,11Z,14Z)-O(5,6)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(8Z,11Z,14Z)-O(5,6)/0:0/2:0)
DG(20:3(8Z,11Z,14Z)-O(5,6)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(20))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(20)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0)
DG(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0/0:0)
DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(6E,8Z,11Z,14Z)-OH(5S))
DG(2:0/0:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0/2:0)
DG(20:4(6E,8Z,11Z,14Z)-OH(5S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(19S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(18R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(17))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(17)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))
DG(2:0/0:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,14Z)-OH(16R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0)
DG(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0/0:0)
DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,11Z,13E)-OH(15S))
DG(2:0/0:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0/2:0)
DG(20:4(5Z,8Z,11Z,13E)-OH(15S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0)
DG(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0/0:0)
DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,8Z,10E,14Z)-OH(12S))
DG(2:0/0:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0/2:0)
DG(20:4(5Z,8Z,10E,14Z)-OH(12S)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0)
DG(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0/0:0)
DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5E,8Z,12Z,14Z)-OH(11R))
DG(2:0/0:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0/2:0)
DG(20:4(5E,8Z,12Z,14Z)-OH(11R)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0)
DG(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0/0:0)
DG(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/20:4(5Z,7E,11Z,14Z)-OH(9))
DG(2:0/0:0/20:4(5Z,7E,11Z,14Z)-OH(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(5Z,7E,11Z,14Z)-OH(9)/0:0/2:0)
DG(20:4(5Z,7E,11Z,14Z)-OH(9)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
Lancifodilactone F
Lancifodilactone F is a tetracyclic triterpenoid that is a rearranged pentanortriterpenoid derived from cycloartane. Isolated from the leaves and stem of Schisandra lancifolia, it exhibits anti-HIV activity. It has a role as a metabolite and an anti-HIV agent. It is an oxaspiro compound, a tetracyclic triterpenoid, a gamma-lactone, a diol and a monocarboxylic acid. A tetracyclic triterpenoid that is a rearranged pentanortriterpenoid derived from cycloartane. Isolated from the leaves and stem of Schisandra lancifolia, it exhibits anti-HIV activity.
Azadirone
A tetracyclic triterpenoid that is 4,4,8-trimethylandrosta-1,14-diene substituted by an oxo group at position 3, an acetoxy group at position 7 and a furan-3-yl group at position 17. Isolated from Azadirachta indica, it exhibits antiplasmodial and antineoplastic activities.
(ent-2alpha,3beta,13Z)-3-Angeloyloxy-8(17),13-labdadiene-2,15,16,18-tetrol
N-{1-[4-(2-methoxyphenyl)piperazin-1-yl]propan-2-yl}-N-(pyridin-2-yl)cyclohexanecarboxamide
13-hydroxy-7-oxolabda-8,14-diene 13(R)-O-alpha-L-arabinopyranoside
6alpha,7beta-diacetoxy-13,14-dihydrokolavenic acid methyl ester
1alpha,6beta,7beta,14beta-tetrahydroxy-20-isobutoxy-7alpha,20-epoxy-ent-kaur-16-en-15-one|hebeirubescensin D
9,10-epoxy-6alpha-O-tigloyl-7alphaH-8beta-O-(3-hydroxy-2-methylbutyryl)germacra-3(4)E-ene|trijugin H
14,15-dihydroclerodin|clerodin|dihydroclerodin|dihydroclerodin-1|dihydroclerodin-I
2,3-Dihydroxy-24,29-dinor-1,3,5(10),7-friedelatetraene-6,21-dione|6-oxotingenol
2beta,3alpha-Dihydroxy-ent-labd-7-en-15-oic acid methyl ester diacetate
3beta,8alpha,13,14-erythro-tetrahydroxy-labda-15,17-dien-16,19-olide
12,13-Di-Ac-(4xi,6beta,9alpha,12xi,13xi)-2,10(18),14-Prenylguaiatriene-4,6,9,12,13-pentol
1alpha,3beta,15beta-trihydroxy-7beta,11beta-diacetoxy-ent-kaur-16-ene|nervonin H
16-(2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl)-17-nor-coryn-19-ene|4,17-dihydro 17 alpha-tchibangensine
6alpha,11beta,15beta-trihydroxy-3beta,7beta-diacetoxy-ent-kaur-16-ene|xindongnin E
(22R)-4beta-hydroxy-1-oxo-witha-2,5,16,24-tetraenolide|(4S,20S,22R)-4-hydroxy-1-oxo-witha-2,5,16,24-tetraenolide
12,13-Di-Ac-(3beta,6beta,9alpha,12xi,13xi)-4,10,14-Prenylguaiatriene-3,6,9,12,13-pentol
(2alpha,3alpha,7alpha,12?鈥?13?鈥?-3-(2-Methylbutanoyl):2,3,7-Trihydroxy-8(17)-labden-15,12-olide|2alpha,7alpha-dihydroxy-3alpha(2-methylbutanoyloxy)8(17)-labden-12,15-olide
19-(p-hydroxyhydrocinnamoyloxy)-ent-kaurenic acid|19--ent-kaurenic acid
12beta-O-acetyl-15alpha,28-dihydoxy-17beta-methoxy-3-oxo-20,21,22,23,24,25,26,27-octanordammanran
6alpha,8alpha,15(S),23-tetrahydroxy-labd-13(14),17-dien-16(S),19-olide
(5S,8R,9S,10R,13S)-2-oxo-13-O-arabinopyranosyl-3,14-clerodadiene
7alpha,14beta-dihydroxy-17alpha-ethoxymethyl-3beta-acetoxy-ent-kaur-11,15-dione
3,3-dimethylundecan-2-yl 4-acetyl-2,3,6-trimethoxybenzoate|asiatoate A
20(S)-1alpha,6beta,7beta-trihydroxy-20-butoxy-8,15-seco-7alpha,20-epoxy-ent-kaur-16-en-11,15-olide|parvifoline Y
9,10-epoxy-5beta-O-tigloyl-7alphaH-6alpha,8beta-di-O-acetylgermacra-3(4)E-ene|trijugin B
15,16-diacetoxy-12,13-15,16-diepoxy-14-hydroxy-neoclerod-3-ene
3,9-dihydroxy-4,6a,6b,8a,11,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(20S,22S,23R,24S)-14beta,22:22,25-diepoxy-23-hydroxyergosta-4,6,8,11-tetraen-3-one|blazeispirol U
9alpha,13alpha-diacetoxy-11(15->1)abeotaxa-4(20),11-diene-5alpha,10beta,15-triol
6alpha,7alpha-17beta-trihydroxy-15beta,17-oxidispongian-16-one 7-butyrate|aplyroseol-3
(3aS,5R,5aS,6aS,7aS,8R,8aS,8bR)-dodecahydro-3a,8b-dihydroxy-5,7a-dimethyl-1-methylideneoxireno[6,7]naphtho[2,1-b]furan-8-yl decanoate|strobilol I
6alpha-hydroxy-17-(alpha-methylbutyroxy)grindelic acid
5alpha,13alpha-dihydroxy-9alpha,10beta-diacetoxy-11(15->1)-abeo-taxa-4(20),11-diene
16-(2,3,4,9-tetrahydro-1H-beta-carbolin-1-yl)-16-nor-coryn-3(14)-ene|3-Dehydrochrolifuanin|3-Dehydroochrolifuanin
Simvastatin acid
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor
PA(18:1/0:0)
C21H41O7P (436.25897660000004)
Oleoyl lysophosphatidic acid
C21H41O7P (436.25897660000004)
(5Z,7E)-(1S,3R)-24-methylsulfonyl-9,10-seco-5,7,10(19)-cholatriene-1,3-diol
1-Oleoyl Lysophosphatidic Acid (sodium salt)
C21H41O7P (436.25897660000004)
(R)-1-O-[b-D-Apiofuranosyl-(1->2)-b-D-glucopyranoside]-1,3-octanediol
LPA 18:1
C21H41O7P (436.25897660000004)
1alpha-hydroxy-24-methylsulfonyl-25,26,27-trinorvitamin D3
N-[2-[4-(2-METHOXYPHENYL)PIPERAZINO]-1-METHYLETHYL]-N-PYRIDIN-2-YLCYCLOHEXANECARBOXAMIDE
bialamicol
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
Bolmantalate
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
Lifarizine
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C93038 - Cation Channel Blocker
2-Dicyclohexylphosphino-2,6-bis(N,N-dimethylamino)biphenyl
C28H41N2P (436.30071960000004)
FGIN-1-27
C28H37FN2O (436.28897639999997)
D006133 - Growth Substances > D010937 - Plant Growth Regulators > D007210 - Indoleacetic Acids
(trans,trans)-4-Pentyl-[1,1-bicyclohexyl]-4-carboxylic acid 4-ethoxy-2,3-difluorophenyl ester
dodecyl 2-methylprop-2-enoate,3,3,3-trifluoropropyl 2-methylprop-2-enoate
Cipemastat
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors > D061965 - Matrix Metalloproteinase Inhibitors C471 - Enzyme Inhibitor > C783 - Protease Inhibitor > C1970 - Matrix Metalloproteinase Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor
N~2~-1,3-Benzoxazol-2-YL-3-cyclohexyl-N-{2-[(4-methoxyphenyl)amino]ethyl}-L-alaninamide
C25H32N4O3 (436.24742819999994)
pangamic acid
1-Stearoyl-sn-glycero-3-phosphate(2-)
C21H41O7P-2 (436.25897660000004)
(2S)-2-azaniumyl-5-[[(2R)-1-[[2-[4-(3-azaniumylpropylazaniumyl)butylamino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoate
C17H36N6O5S+2 (436.24677660000003)
2-Stearoyl-sn-glycerol 3-phosphate
C21H41O7P-2 (436.25897660000004)
[(2R)-2-hydroxy-3-phosphonooxypropyl] (E)-octadec-11-enoate
C21H41O7P (436.25897660000004)
[(2R)-2-hydroxy-3-phosphonooxypropyl] (Z)-octadec-11-enoate
C21H41O7P (436.25897660000004)
3-[2-[(3S,5R,8R,9S,10S,13R,14S,17S)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-3-oxopropanoic acid
14,15-Dihydroclerodin
A diterpenoid isolated from the aerial parts of Ajuga bracteosa and has been shown to exhibit antifeedant activity.
1-Palmityl-2-acetyl-sn-glycero-3-phosphate(2-)
C21H41O7P-2 (436.25897660000004)
N-[2-(cyclopentylamino)-2-oxoethyl]-N-(3,4-dimethylphenyl)-N-(2-pyridinyl)pentanediamide
C25H32N4O3 (436.24742819999994)
6,8-dimethyl-3-[(3-methyl-1-piperidinyl)-[1-(2-oxolanylmethyl)-5-tetrazolyl]methyl]-1H-quinolin-2-one
C24H32N6O2 (436.25866119999995)
N-[2-(cyclopentylamino)-2-oxoethyl]-N-(4-methoxyphenyl)-6-(1-piperidinyl)-3-pyridinecarboxamide
C25H32N4O3 (436.24742819999994)
2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
C21H35F3N2O4 (436.25487860000004)
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
C21H35F3N2O4 (436.25487860000004)
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
C21H35F3N2O4 (436.25487860000004)
(10S,11S)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10S,11R)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
2-[(3S,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
C21H35F3N2O4 (436.25487860000004)
2-[(3S,6aS,8R,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
C21H35F3N2O4 (436.25487860000004)
(10S,11S)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11S)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
C21H35F3N2O4 (436.25487860000004)
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-(3,3,3-trifluoropropyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(cyclohexylmethyl)acetamide
C21H35F3N2O4 (436.25487860000004)
(2S,3S,3aR,9bR)-N-(cyclohexylmethyl)-3-(hydroxymethyl)-1-methyl-6-oxo-7-(3-pyridinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C25H32N4O3 (436.24742819999994)
(2R,3R,3aS,9bS)-N-(cyclohexylmethyl)-3-(hydroxymethyl)-1-methyl-6-oxo-7-(3-pyridinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-2-carboxamide
C25H32N4O3 (436.24742819999994)
4-[(3aR,4R,9bR)-1-[2-(dimethylamino)-1-oxoethyl]-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]-N,N-dimethylbenzamide
C25H32N4O3 (436.24742819999994)
(10R,11S)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
(10R,11R)-10-[[cyclopropylmethyl(methyl)amino]methyl]-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-14-one
2-[(E)-5-[(1R,2R,4S,5S,6R,8aS)-2,4,6-trihydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-enyl]-3-methyl-2H-uran-5-one
[(E)-2-(hexanoylamino)-3-hydroxynon-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-2-acetamido-3-hydroxytridec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-3-hydroxy-2-(pentanoylamino)dec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-3-hydroxy-2-(propanoylamino)dodec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-2-(butanoylamino)-3-hydroxyundec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
[(E)-2-(heptanoylamino)-3-hydroxyoct-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate
C20H41N2O6P (436.27020960000004)
1-Oleoyl-sn-glycerol 3-phosphate
C21H41O7P (436.25897660000004)
A 1-acyl-sn-glycerol 3-phosphate having oleoyl as the 1-O-acyl group.
1-Stearoyl-sn-glycero-3-phosphate(2-)
C21H41O7P (436.25897660000004)
A 1-acyl-sn-glycerol 3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-stearoyl-sn-glycero-3-phosphate.
2-hydroxy-3-(phosphonooxy)propyl octadec-9-enoate
C21H41O7P (436.25897660000004)
6-[2,2-Bis[di(propan-2-yl)amino]acetyl]oxy-2,3,4,5-tetrahydroxyhexanoic acid
Paraminabeolide A
A withanolide that is 22,26-epoxyergosta-1,4,24-triene-18-al substituted by oxo groups at positions 3 and 26. Isolated from a Formosan soft coral, Paraminabea acronocephala, it exhibits cytotoxic activity.
2-oleoyl-sn-glycero-3-phosphate
C21H41O7P (436.25897660000004)
A 2-acyl-sn-glycerol 3-phosphate in which the phosphatidyl acyl group is specified as oleoyl.
1-Palmityl-2-acetyl-sn-glycero-3-phosphate(2-)
C21H41O7P (436.25897660000004)
A 1-alkyl-2-acyl-sn-glycero-3-phosphate(2-) obtained by deprotonation of the phosphate OH groups of 1-palmityl-2-acetyl-sn-glycero-3-phosphate; major species at pH 7.3.
1-octadec-9-enoylglycero-3-phosphate
C21H41O7P (436.25897660000004)
Glutathionylspermidinium(2+)
C17H36N6O5S (436.24677660000003)
Dication of glutathionylspermidine arising from deprotonation of the terminal carboxy group and protonation of the primary and secondary amino groups; major species at pH 7.3.
TG(22:3)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LPEt(16:1)
C21H41O7P (436.25897660000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(1s,3br,4r,5ar,9ar,9br,11as)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
(2r,3s,4r,5r)-6-{[2,2-bis(diisopropylamino)acetyl]oxy}-2,3,4,5-tetrahydroxyhexanoic acid
[8-(acetyloxy)-5-(1,3-dihydroxy-3-methylpent-4-en-1-yl)-1,5,6-trimethyl-2-oxo-4,6,7,8-tetrahydro-3h-naphthalen-1-yl]methyl acetate
3,18-dihydroxy-5,5,9-trimethyl-14-oxo-15,17-dioxapentacyclo[11.5.1.0¹,¹⁰.0⁴,⁹.0¹⁶,¹⁹]nonadecan-2-yl butanoate
(2r,3r,4s,6r,7s)-2-{[(1s,2r,4ar,8ar)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl}-4-(acetyloxy)-7-hydroxy-1,5-dioxaspiro[2.4]heptan-6-yl acetate
2-[(1as,2r,2as,3r,5's,6ar,7s,7as)-3,7-dihydroxy-1a,2a,5',6,6-pentamethyl-hexahydrospiro[naphtho[2,3-b]oxirene-2,2'-oxolan]-5'-yl]ethyl 3-methylbut-2-enoate
2,3-dimethoxy-5-methyl-6-[(2e,6z,9e)-3,7,9-trimethyl-11-phenylundeca-2,6,9-trien-1-yl]pyran-4-one
ethyl (3r,5r)-7-[(1s,2s,8s,8ar)-2-methyl-8-{[(2s)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
(1'r,2s,3r,4s,10's,14'r,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2'(11'),3',5',12'-tetraen-7'-one
1-[1-(4,5-dihydroxy-3-methylidenepentyl)-1,4a,5-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-2-yl]methyl 4-methyl butanedioate
{5-[(acetyloxy)methyl]-1-[2-(5-methoxyoxolan-3-yl)ethyl]-1,2-dimethyl-2,3,4,7,8,8a-hexahydronaphthalen-4a-yl}methyl acetate
(1s,2s,4r,6s,8s,9r,10s,11s,13s,15r)-6-(acetyloxy)-8,11,15-trihydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-2-yl acetate
6-(acetyloxy)-3,8,11-trihydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-15-yl acetate
(1r,5r,8r)-8-[(1r,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(2r)-2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-yl acetate
(1s,3s,4r,6s,8s,9s,10r,11s,13s,15r)-6-(acetyloxy)-8,11,15-trihydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-3-yl acetate
(1r,5s,7r)-7-[(1s,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(1r,3bs,4r,5ar,9as,9bs,11as)-1-(furan-3-yl)-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,9bh,10h,11h-cyclopenta[a]phenanthren-4-yl acetate
(1r,3s,4r,6s,8s,9r,10r,11s,13s,15r)-6-(acetyloxy)-3,8,11-trihydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-15-yl acetate
1,16-dihydroxyhexadecan-7-yl 3-(3,4-dihydroxyphenyl)prop-2-enoate
(1s,2s,3s,4s,5s,6e,10r)-2,4-bis(acetyloxy)-3-isopropyl-6,10-dimethyl-11-oxabicyclo[8.1.0]undec-6-en-5-yl (2e)-2-methylbut-2-enoate
(1r,2s,5s,6r,10r,11s,12r,15r,19s)-11-ethoxy-6-(furan-3-yl)-1,5,10,15-tetramethyl-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadeca-8,16-dien-18-one
(2r,3r,4s,5r)-3,5-dihydroxy-2-[(3,7,11-trimethyldodeca-2,6,10-trien-1-yl)oxy]oxan-4-yl 2-methylbut-2-enoate
(6bs,7s,8as,11r,12ar,12bs,14as)-3,7-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
ethyl 3,5-dihydroxy-7-{2-methyl-8-[(2-methylbutanoyl)oxy]-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}heptanoate
1-[(1r,2r,4ar,8ar)-1-[(4s)-4,5-dihydroxy-3-methylidenepentyl]-1,4a,5-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-2-yl]methyl 4-methyl butanedioate
5-[4-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-6-[(3-methylbutanoyl)oxy]-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-2-enoic acid
(8ar,9s,10r,11s,12as,12bs,14as)-3,9,10-trihydroxy-4,7,8a,11,12b,14a-hexamethyl-8,9,10,11,12,12a,13,14-octahydropicen-2-one
methyl (3r)-5-[(1r,2s,3r,4r,4ar,8ar)-3,4-bis(acetyloxy)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpentanoate
(1s,2r,3r,4s,6s,9s,10s,11s,13s,15r)-6-(acetyloxy)-2,11,15-trihydroxy-5,5,9-trimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-3-yl acetate
6-oxotingenol
{"Ingredient_id": "HBIN012741","Ingredient_name": "6-oxotingenol","Alias": "NA","Ingredient_formula": "C28H36O4","Ingredient_Smile": "CC1CC2C(CCC3(C2(CCC4(C3=CC(=O)C5=C(C(=C(C=C54)O)O)C)C)C)C)(CC1=O)C","Ingredient_weight": "436.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "16418","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "10410773","DrugBank_id": "NA"}
1-{5-[7-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-2-en-1-yl} 4-methyl butanedioate
(1'r,2s,3r,4s,10's,14's,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2'(11'),3',5',12'-tetraen-7'-one
methyl 5-[3,4-bis(acetyloxy)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]-3-methylpentanoate
(2e)-n-[(3s,7r,10r)-2,9-dihydroxy-3-isopropyl-7-methyl-5,6-dioxo-1,4,8-triazacyclotrideca-1,8-dien-10-yl]-6-methylhept-2-enimidic acid
(1r,5s,8r)-8-[(1r,3as,3bs,9ar,9bs,11as)-9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
(2s,3e,12bs)-3-ethylidene-2-[(1s)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl]-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
4-hydroxy-5,5,5',8a-tetramethyl-2-{[(2-methylbutanoyl)oxy]methyl}-4a,6,7,8-tetrahydro-4h-spiro[naphthalene-1,2'-oxolan]-5'-ylacetic acid
methyl (1r,2r,4ar,5s,8ar)-2-(acetyloxy)-5-[(3s)-5-(acetyloxy)-3-methylpentyl]-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylate
3-ethylidene-2-{1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl}-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
(6bs,8as,11r,12ar,12bs,14ar)-3-hydroxy-11-(hydroxymethyl)-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,10,12,12a,13,14-octahydropicen-2-one
3-ethenyl-2-{1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl}-1h,2h,3h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
7-{9a,11a-dimethyl-9-oxo-1h,2h,3h,3ah,3bh,4h,6h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}-5-methyl-4-methylidene-2,6-dioxabicyclo[3.3.1]nonan-3-one
1-[(1s,2r,4as,8ar)-1-[(3r)-4-methoxy-3-methyl-4-oxobutyl]-1,2,5-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-4a-yl]methyl 4-methyl butanedioate
(6bs,8ar,9s,11r,12as,12bs,14ar)-3,9-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(2r)-2-[(3s,3as,5as,7s,8r,10ar,10br)-8-[(2s)-1,2-dihydroxypropan-2-yl]-3a,10b-dimethyl-5'-oxo-decahydro-1h-spiro[cyclohepta[e]indene-7,2'-oxolan]-3-yl]propanoic acid
(2r,3r,4s,5r)-3,5-dihydroxy-2-{[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy}oxan-4-yl (2z)-2-methylbut-2-enoate
(1'r,2s,3r,4s,14's,15'r,16's)-3-hydroxy-4,5,5,10',14',16'-hexamethyl-18'-oxaspiro[oxolane-2,17'-pentacyclo[13.3.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosane]-2'(11'),3',5',12'-tetraen-7'-one
1-[1-(4-methoxy-3-methyl-4-oxobutyl)-1,2,5-trimethyl-2,3,4,7,8,8a-hexahydronaphthalen-4a-yl]methyl 4-methyl butanedioate
11-hydroxy-10-methoxy-2,4a,6a,9,12b,14a-hexamethyl-2,4,5,6,6b,13,14,14b-octahydro-1h-picen-3-one
(6ar,6br,8as,11r,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydro-6ah-picene-2,6,10-trione
(5s)-5-[(2e)-5-[(1r,2r,4s,4ar,5r,6s,8as)-2,4,6-trihydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-hexahydro-1h-naphthalen-1-yl]-3-methylpent-2-en-1-yl]-4-methyl-5h-furan-2-one
methyl (1r,4s,5r,9s,10s,13r,15s)-15-(benzoyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate
methyl 2-(acetyloxy)-5-[5-(acetyloxy)-3-methylpentyl]-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalene-1-carboxylate
2,8-dimethyl-2-[(3e,7e)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]chromen-6-yl acetate
2-[8-(1,2-dihydroxypropan-2-yl)-3a,10b-dimethyl-5'-oxo-decahydro-1h-spiro[cyclohepta[e]indene-7,2'-oxolan]-3-yl]propanoic acid
(2s,3r,12bs)-3-ethenyl-2-[(1r)-1h,2h,3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl]-1h,2h,3h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
(6as,6br,8as,11r,12ar,12bs,14ar)-3-hydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydro-6ah-picene-2,6,10-trione
(3ar,7r,7as)-6-[(3ar,9r,9as)-9-hydroxy-2,2,9-trimethyl-4-oxo-1h,3h,3ah,9ah-cyclopenta[b]naphthalen-6-yl]-7-hydroxy-2,2,7-trimethyl-1,3,3a,7a-tetrahydroinden-4-one
7-{5-[(1s,2r,4ar,8ar)-1,2,4a,5-tetramethyl-7-oxo-3,4,8,8a-tetrahydro-2h-naphthalen-1-yl]-3-methylpent-2-en-1-yl}-6-amino-9-methylpurin-9-ium
[(1s,4s,5r,9s,10r,13r)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl]methyl 3-(4-hydroxyphenyl)propanoate
methyl (3r,5r)-7-[(1s,2s,6r,8s,8ar)-2,6-dimethyl-8-{[(2s)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate
1-{5-[2-(5-methoxyoxolan-3-yl)ethyl]-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl}methyl 3-methyl propanedioate
(2s,3s,4r,5r)-2-{[(3e)-4-[(2r,3r)-3-[(3r,4r)-4-ethenyl-4-methyl-3-(prop-1-en-2-yl)cyclohexyl]-3-methyloxiran-2-yl]-2-methylbut-3-en-2-yl]oxy}oxane-3,4,5-triol
(7r)-1,16-dihydroxyhexadecan-7-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
(2s,3r)-2-[(2s,4r,6e)-4,6-dimethyloct-6-en-2-yl]-6-oxooxan-3-yl (2e,4e,6r)-8-hydroxy-6-(hydroxymethyl)-4-methylocta-2,4-dienoate
methyl 15-(benzoyloxy)-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate
2-oxatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3,5,7(29),13,16,24,27-octaene-5,26,27-triol
3,7-dihydroxy-1,1,4a-trimethyl-5-[(3-methyl-5-oxooxolan-2-yl)methyl]-6-methylidene-hexahydro-2h-naphthalen-2-yl 2-methylbutanoate
(9z,12z)-n-[2-(1h-indol-3-yl)-2-oxoethyl]octadeca-9,12-dienimidic acid
3,9-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
(1r,2r,10r,11s,14r,15r,16s)-16-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-10,14,16-trimethyl-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadeca-4,6-dien-9-one
(6bs,8as,11s,12ar,12bs,14ar)-3,11-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
1-[(4ar,5s,6r,8ar)-5-{2-[(3s,5s)-5-methoxyoxolan-3-yl]ethyl}-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl 3-methyl propanedioate
(14z,17z)-2-oxatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3,5,7(29),14,17,24,27-octaene-5,26,27-triol
(6bs,8as,11r,12ar,14ar)-3,11-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-8,9,12,12a,13,14-hexahydro-7h-picene-2,10-dione
(4as,8as)-3,4a,8,8-tetramethyl-4-[(3r)-3-methyl-3-{[(2s,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}pent-4-en-1-yl]-5,6,7,8a-tetrahydro-1h-naphthalen-2-one
10,11-dihydroxy-2,4a,6a,9,12b,14a-hexamethyl-1,2,4,5,6,13,14,14b-octahydropicene-3,8-dione
(2s,3r,4as,5r,7r,8ar)-3,7-dihydroxy-1,1,4a-trimethyl-5-{[(2s,3r)-3-methyl-5-oxooxolan-2-yl]methyl}-6-methylidene-hexahydro-2h-naphthalen-2-yl (2r)-2-methylbutanoate
2,6-dihydroxy-8,13-dimethyl-3-methylidene-5,12-dioxatetracyclo[7.5.0.0²,⁶.0¹¹,¹³]tetradecan-14-yl decanoate
2,8-dimethyl-2-(4,8,12-trimethyltrideca-3,7,11-trien-1-yl)chromen-6-yl acetate
3,7-dihydroxy-4,6b,8a,11,12b,14a-hexamethyl-7,8,9,11,12,12a,13,14-octahydropicene-2,10-dione
3,4a,8,8-tetramethyl-4-{3-methyl-3-[(3,4,5-trihydroxyoxan-2-yl)oxy]pent-4-en-1-yl}-5,6,7,8a-tetrahydro-1h-naphthalen-2-one
n-[2-(1h-indol-3-yl)-2-oxoethyl]octadeca-9,12-dienimidic acid
6-amino-7-[(2e)-3,7-dimethyl-9-[(1r,6s)-1,2,6-trimethyl-4-oxocyclohex-2-en-1-yl]nona-2,6-dien-1-yl]-9-methylpurin-9-ium
(1s,4s,4as,5'r,8as)-4-hydroxy-5,5,5',8a-tetramethyl-2-({[(2r)-2-methylbutanoyl]oxy}methyl)-4a,6,7,8-tetrahydro-4h-spiro[naphthalene-1,2'-oxolan]-5'-ylacetic acid
(1s,2r,6s,8r,9s,11s,13s,14r)-2,6-dihydroxy-8,13-dimethyl-3-methylidene-5,12-dioxatetracyclo[7.5.0.0²,⁶.0¹¹,¹³]tetradecan-14-yl decanoate
1-[(4ar,5s,6r,8ar)-5-{2-[(3s,5r)-5-methoxyoxolan-3-yl]ethyl}-5,6,8a-trimethyl-3,4,4a,6,7,8-hexahydronaphthalen-1-yl]methyl 3-methyl propanedioate
(3r)-n-{2-[(1e,7ar)-3-oxo-tetrahydropyrrolo[1,2-c][1,3]oxazol-1-ylidene]acetyl}-3-hydroxyhexadecanimidic acid
C24H40N2O5 (436.29370700000004)
3-hydroxy-5-[5-hydroxy-3-(hydroxymethyl)pent-3-en-1-yl]-1-(hydroxymethyl)-1,4a-dimethyl-6-methylidene-hexahydro-2h-naphthalen-2-yl 2-methylbut-2-enoate
{5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecan-5-yl}methyl 3-(4-hydroxyphenyl)propanoate
(1s,4ar,5s,8ar)-1,4a-dimethyl-5-[(3e)-3-methyl-5-{[(2r,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pent-3-en-1-yl]-6-methylidene-hexahydro-2h-naphthalene-1-carbaldehyde
[(1s,2s,3r,5r,10r,11r,14s,16r,17r)-3,17-dihydroxy-2,7,7,10-tetramethyl-6,8-dioxapentacyclo[14.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosan-17-yl]methyl acetate
{3,17-dihydroxy-2,7,7,10-tetramethyl-6,8-dioxapentacyclo[14.3.1.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]icosan-17-yl}methyl acetate
(2r,4as,6ar,6bs,12br,14as,14br)-11-hydroxy-10-methoxy-2,4a,6a,9,12b,14a-hexamethyl-2,4,5,6,6b,13,14,14b-octahydro-1h-picen-3-one
4-methyl-5-[(2z)-3-methyl-5-[2,4,6-trihydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-hexahydro-1h-naphthalen-1-yl]pent-2-en-1-yl]-5h-furan-2-one
(5e)-5-[(2s,3s)-5-[(1r,2r,4ar,6s,8as)-2,6-dihydroxy-2,5,5,8a-tetramethyl-hexahydro-1h-naphthalen-1-yl]-2,3-dihydroxy-3-methylpentylidene]-4-methylfuran-2-one
(13z,16z)-2-oxatricyclo[22.2.2.1³,⁷]nonacosa-1(26),3,5,7(29),13,16,24,27-octaene-5,26,27-triol
(2r,3z,12bs)-3-ethylidene-2-{3h,4h,9h-pyrido[3,4-b]indol-1-ylmethyl}-1h,2h,4h,6h,7h,7ah,12h,12ah,12bh-indolo[2,3-a]quinolizine
(2s,3r,4r,5s)-3,5-dihydroxy-2-{[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]oxy}oxan-4-yl (2z)-2-methylbut-2-enoate
1-(2e)-5-[(1s,4ar,5s,7r,8ar)-7-hydroxy-5-(hydroxymethyl)-2,5,8a-trimethyl-1,4,4a,6,7,8-hexahydronaphthalen-1-yl]-3-methylpent-2-en-1-yl 4-methyl butanedioate
(2s)-2-hydroxy-3-[(9z)-octadec-9-enoyloxy]propoxyphosphonic acid
C21H41O7P (436.25897660000004)